Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Next Previous
X
Search
Trial Profile

A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triamcinolone (Primary) ; Triamcinolone
  • Indications Musculoskeletal pain; Pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Flexion Therapeutics

    • Most Recent Events

    • 01 May 2020 Results published in the Flexion Therapeutics media release
    • 01 May 2020 According to a Flexion Therapeutics media release, data from this study was accepted as abstracts at Osteoarthritis Research Society International (OARSI) OARSI 2020 and published in the Osteoarthritis & Cartilage journal.
    • 26 Dec 2019 According to an Flexion Therapeutics media release, the company will host a conference call to discuss the supplemental New Drug Application (sNDA) approval.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top